Mission Statement
Improve the health of individuals and communities with respect to addiction-prone substances.

Vision Statement
To use prevention and intervention research and training to influence how communities, governments, policy makers, providers, and people make choices regarding addiction-prone substances to prevent addiction and overdose death.

Our collaborative, multi-state, interdisciplinary team model will utilize academic research and practitioner strategies to conduct research and educate.

Description of Business
The Schreiber Research Group is uniquely situated to fill knowledge gaps about addiction-prone substances. Our team brings decades of expertise on opioid prescribing, addiction medicine, chronic pain management, public policy analysis, and fundraising to inform our research and aid our pursuit of practical solutions. Our collaborative model enables our team to cut across academic, clinical, and practitioner disciplines to pursue generalizable and operationalizable solutions to some of the most compelling questions that surround the opioid crisis.

One of Our goal is to share providers who adopt our core principles when it comes to prescribing opioids:


  • Opioids are one treatment option. They come with risks but can be a useful treatment option if those risks are understood and mitigated.


  • Co-prescribing benzodiazepines and opioids account for up to 50% of all opioid related deaths and are not intended for chronic use.


  • When treating a patient (new or existing) non-opioid alternatives, opioids, and surgery should be considered. Non-opioid treatment should always be considered first.

AHIP: 25% of Opioid Prescriptions Top CDC Dosage Guidelines

  • Awareness of (OIH) opioid induced hyperalgesia is essential for understanding pain response and treatment plan efficacy.

“The International Association for the Study of Pain defines hyperalgesia as increased pain from a stimulus that normally provokes pain . Opioid induced hyperalgesia (OIH) is a state of enhanced pain sensitization in patients who are on chronic opioid therapy (COT).”

Peter Yi, Peter Pryzbylkowski; Opioid Induced Hyperalgesia, Pain Medicine, Volume 16, Issue suppl_1, 1 October 2015, Pages S32–S36,

Roeckel, Le Coz, Gavériaux-Ruff, & Simonin. (2016). Opioid-induced hyperalgesia: Cellular and molecular mechanisms. Neuroscience, 338, 160-182.

  1. PDMPs or data analytics tools are reviewed every time I make a prescribing decision regarding opioids.